Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL...
-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
(3)
•••
badbusiness
X
View Profile
View Bullboard History
Comment by
badbusiness
on Dec 06, 2024 11:55am
RE:RE:Medicenna Provides Clinical Update and Announces First Compl
This stock is so undervalued, hidden gem
(93)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Dec 05, 2024 11:14am
RE:Medicenna Provides Clinical Update and Announces First Compl
Never a bad announcement. Hope Merck is taking a strong look and crunching #s!
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 05, 2024 11:00am
Medicenna Provides Clinical Update and Announces First Compl
NEWS: $MDNAF Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study70-year
...more
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Nov 09, 2024 4:19pm
SITC NEWS!!!
Mono therapy ORR of 25% (FDA worthy) And Combo therapy 3 SD and one PR already Yipeee MERCK must be sniffing. https://ir.medicenna.com/static-files/aaddc210-ee56-4905
...more
(93)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Aug 15, 2024 11:15am
RE:Medicenna Reports First Quarter Fiscal 2025 Financial Result
Nice addition to the board today!
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 01, 2024 10:47am
Medicenna Reports First Quarter Fiscal 2025 Financial Result
BREAKING NEWS: $MDNAF Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 MonotherapyPatient with melanoma, having failed dual check-point
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2024 8:19am
New Press Release - Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical developmentResults...
read article.
(93)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Jun 26, 2024 11:55am
RE:RE:RE:RE:Today's news
Nice recovery above $2.00!
(581)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Jun 17, 2024 10:15am
RE:RE:RE:Today's news
Not today .
(93)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Jun 11, 2024 6:00pm
RE:RE:Today's news
#2 Top % gainer today on TSX
(581)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Jun 03, 2024 9:24pm
RE:Today's news
Old news still looking for a partner to help fund a p3 trial
(93)
•••
windymayor1
X
View Profile
View Bullboard History
Post by
windymayor1
on Jun 03, 2024 6:08pm
Today's news
What's it gonna take for this stock to move up on excellent news? Am I missing something here......
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 22, 2024 7:00am
New Press Release - Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 13, 2024 7:00am
New Press Release - Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR 2024 abstract...
read article.
(581)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on May 02, 2024 12:00pm
RE:RE:RE:RE:RE:RE:RE:Surprised and grateful that MDNA ran up over 2.00
I dont but I did buy 20 000 shares below .45
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth